Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 4, 2011, pursuant to shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 685,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,320 pence per share; lowest was 1,303.5 pence per share.
- Treasury Holdings (Settled): 505,396,816 shares (9.07% of total issued share capital).
- Treasury Holdings (Including Unsettled): 505,796,816 shares (9.99% of current total voting rights).
- Shares in Issue (Excluding Treasury): 5,064,615,855 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the cancellation of 685,000 repurchased shares. This action increased the proportion of shares held in Treasury to 9.99% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,064,615,855) for calculating ownership thresholds under Disclosure and Transparency Rules.
- Confirm the impact of the 9.99% Treasury holding on total voting rights.
- Note that the repurchased shares are cancelled, permanently reducing the share count.